The U.K. National Institute for Health and Clinical Excellence has refused to recommend Novartis' Afinitor as second-line therapy for kidney cancer, saying there is "still too much uncertainty" about the drug's cost-effectiveness. The agency has "to ensure that the money available to the [National Health Service] ... is used to best effect, particularly when funds, like the rest of the public sector, is under considerable financial pressure," said NICE CEO Andrew Dillon. Novartis said it intends to appeal the decision.

Related Summaries